THERAPY DOSSIER · th-a42fe3aaacb8

TMMC (2',4',6'-tris(methoxymethoxy) chalcone)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21778460 ↗2011Reported benefit

2',4',6'-Tris(methoxymethoxy) chalcone (TMMC) attenuates the severity of cerulein-induced acute pancreatitis and associated lung injury.

MouseChemical/toxinC57BLPretreatment and posttreatment

Model: Cerulein hyperstimulation acute pancreatitis with lung injury

TMMC reduced the severity of cerulein-induced acute pancreatitis and associated lung injury by inhibiting NF-kB/ERK signalling.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…